Medical News Today (Free subscription) | yesterday
Boston Scientific Corporation (NYSE: BSX) announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from October 12 to 17 in Washington, D.C.
Law Blog - WSJ.com (Free subscription) | yesterday
OCTOBER 11, 2008 Boston Scientific Stent Wins Approval By more in »Boston Scientific Corp. won approval to sell a new heart stent in the U.S., suggesting the medical-device maker may soon be free of a government-imposed moratorium on new products.The company said the Food and Drug Administration approved its Taxus Liberte drug-coated stent, which props open clogged arteries to restore blood flow.An...
Boston Globe (Free subscription) | 10/10/2008
Boston Scientific Corp. said Friday the Food and Drug Administration approved its long-delayed follow-up to the drug-coated stent Taxus.
Red Orbit (Free subscription) | 10/10/2008
-- TAXUS ATLAS Workhorse, Direct Stenting, Small Vessel and Long Lesion studies. Three-year data from the TAXUS ATLAS Workhorse study and two-year data from the TAXUS ATLAS Direct Stent study will be presented by the study's co-principal investigator Mark A. Turco, M.D., in an e-poster session titled "TAXUS ATLAS and TAXUS ATLAS DIRECT STENT Trials: Durable Effectiveness of the TAXUS Liberte Stent...
The Boston Business Journal (Free subscription) | 10/10/2008
Boston Scientific Corp. CEO James Tobin exercised options on Thursday to buy more than 350,000 shares worth about $2.1 million, following a week of dramatic price declines and mixed news for the company. (BSX) (JNJ)
Market Watch (Free subscription) | 10/10/2008
BOSTON (MarketWatch) -- Boston Scientific Corp. said Friday that the Food and Drug Administration has approved its next-generation drug-coated coronary stent Taxus Liberte. The company said it plans to launch the product in the U.S. in early November. The Taxus Liberte has been on the market overseas since 2005. U.S. approval for the device had been delayed by the issuance of a letter by the Food...
DealBook (Free subscription) | 10/10/2008
The bankruptcy of Lehman Brothers has taken a toll on Boston Scientific, the medical device maker, forcing the founders to sell some 13 million shares, the company said Thursday. Sale of the shares by the Boston Scientific founders, Peter M. Nicholas and John Abele, and those held by a trust for Mr. Abele’s children was forced [...]
Anti-Strib (Free subscription) | 09/10/2008
BOSTON SCIENTIFIC COMMENTS ON INVOLUNTARY SELLINGOF ITS STOCK BY CO-FOUNDERS Natick, MA (October 9, 2008) -- Yesterday saw heavy trading in Boston Scientific’s (NYSE: BSX) stock, with approximately 38 million shares traded. This trading included involuntary sales of approximately 13 million shares beneficially owned by Boston Scientific’s co-founders Pete Nicholas and John Abele or held, directly or...
Boston Globe (Free subscription) | 09/10/2008
Shares of Boston Scientific dropped to a 52-week low Thursday a day after the involuntary sell-off of 13 million shares by the medical device firm's co-founders.
The Minneapolis/St. Paul Business Journal (Free subscription) | 09/10/2008
Boston Scientific Corp. will make big adjustments to its third-quarter earnings results to be reported on Oct. 31, thanks in part to losing a $703 million patent infringement lawsuit. (BSX) (JNJ) (ABT)
Times of the Internet (Free subscription) | 09/10/2008
Boston Scientific Corp (NYSE: BSX), which is the world's leading seller of stents that are used in open heart surgeries, has announced a series of charges for the third quarter, related to their loss in a patent infringement case with Johnson and Johnson. The company says it will record up to 15 cents per share for the charges. Included in the quarterly charges will be a $334 million pretax charge...
Boston Globe (Free subscription) | 09/10/2008
Boston Scientific Corp. said Thursday a major sell-off of its stock by its co-founders was involuntary and did not reflect on the company's performance.
Medical News Today (Free subscription) | 09/10/2008
Boston Scientific Corporation (NYSE: BSX) announced that it has completed enrollment in the PERSEUS trial, designed to evaluate the Company's third-generation TAXUS(R) Element(TM) paclitaxel-eluting coronary stent. The PERSEUS clinical program has enrolled nearly 1,500 patients at 100 U.S.
Boston Globe (Free subscription) | 08/10/2008
Boston Scientific said Wednesday it will report up to $514 million in charges for the third quarter, due to a negative ruling in a patent dispute and other impairment charges.
The Boston Business Journal (Free subscription) | 08/10/2008
State Street Corp. surged while Boston Scientific retreated as Massachusetts stocks turned in mixed results at the end of a roller coaster day on the markets. The Dow Jones Industrial Average ended down 191 points, or 2 percent, to close at 9256. (STT) (FMD) (BSX) (BIIB) (GENZ) (SOV) (RTN) (EMC) (BPFH) (EV) (BAC) (BXP)
